SG11201900171QA - Antibody for anti-claudin 18a2 and use thereof - Google Patents

Antibody for anti-claudin 18a2 and use thereof

Info

Publication number
SG11201900171QA
SG11201900171QA SG11201900171QA SG11201900171QA SG11201900171QA SG 11201900171Q A SG11201900171Q A SG 11201900171QA SG 11201900171Q A SG11201900171Q A SG 11201900171QA SG 11201900171Q A SG11201900171Q A SG 11201900171QA SG 11201900171Q A SG11201900171Q A SG 11201900171QA
Authority
SG
Singapore
Prior art keywords
claudin
antibody
methods
immune effector
present
Prior art date
Application number
SG11201900171QA
Inventor
Peng Wang
Hua Jiang
Linlin Yang
Zhimin Shi
Huamao Wang
Zonghai Li
Original Assignee
Carsgen Therapeutics Co Ltd
Shanghai Cancer Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2017/082024 external-priority patent/WO2017186121A1/en
Application filed by Carsgen Therapeutics Co Ltd, Shanghai Cancer Inst filed Critical Carsgen Therapeutics Co Ltd
Publication of SG11201900171QA publication Critical patent/SG11201900171QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)

Abstract

Provided in the present invention is an antibody for anti-claudin 18A2 and an immune effector cell targeting claudin 18A2. Also provided are methods for inducing cell death and treating tumours. Fig. 3
SG11201900171QA 2016-07-08 2017-07-10 Antibody for anti-claudin 18a2 and use thereof SG11201900171QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610536449 2016-07-08
PCT/CN2017/082024 WO2017186121A1 (en) 2016-04-26 2017-04-26 Method for improving function of immune response cell
PCT/CN2017/092381 WO2018006882A1 (en) 2016-07-08 2017-07-10 Antibody for anti-claudin 18a2 and use thereof

Publications (1)

Publication Number Publication Date
SG11201900171QA true SG11201900171QA (en) 2019-02-27

Family

ID=60912336

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900171QA SG11201900171QA (en) 2016-07-08 2017-07-10 Antibody for anti-claudin 18a2 and use thereof

Country Status (12)

Country Link
US (2) US11111295B2 (en)
EP (1) EP3483182B1 (en)
JP (1) JP2019531084A (en)
KR (1) KR20190038564A (en)
CN (1) CN109790222B (en)
AU (1) AU2017294276A1 (en)
BR (1) BR112019000327A8 (en)
CA (1) CA3030257A1 (en)
CL (1) CL2019000061A1 (en)
IL (1) IL264144B2 (en)
SG (1) SG11201900171QA (en)
WO (1) WO2018006882A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3483182B1 (en) * 2016-07-08 2024-05-08 CRAGE medical Co., Limited Antibody for anti-claudin 18a2 and use thereof
JP2021512875A (en) 2018-02-02 2021-05-20 カースゲン セラピューティクス カンパニー リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． Combination of cell immunotherapy
JP7398380B2 (en) 2018-03-08 2023-12-14 フェインズ セラピューティクス，インコーポレーテッド Anti-claudin 18.2 antibody and its use
US20220110973A1 (en) * 2018-03-09 2022-04-14 Cafa Therapeutics Limited Method and composition for treating tumors
SG11202006217YA (en) * 2018-03-14 2020-07-29 Beijing Xuanyi Pharmasciences Co Ltd Anti-claudin 18.2 antibodies
US20220127570A1 (en) * 2018-05-03 2022-04-28 Cafa Therapeutics Limited Immune effector cell and use thereof
CA3100446A1 (en) 2018-05-15 2019-11-21 Carsgen Therapeutics Co., Ltd. Genetically engineered cell and application thereof
EP3794037A4 (en) 2018-05-18 2022-03-02 Lanova Medicines Limited Company Anti-claudin 18.2 antibodies and uses thereof
WO2020020210A1 (en) 2018-07-24 2020-01-30 科济生物医药（上海）有限公司 Method for treating tumor using immune effector cell
EP3826612A4 (en) * 2018-07-25 2022-09-14 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
CN110857322A (en) * 2018-08-22 2020-03-03 瑞阳(苏州)生物科技有限公司 Anti-human claudin18.2 monoclonal antibody and application thereof
WO2020043044A1 (en) * 2018-08-27 2020-03-05 南京圣和药业股份有限公司 Anti-claudin18.2 antibody and use thereof
CN109206524B (en) * 2018-09-25 2022-04-05 山东兴瑞生物科技有限公司 anti-Claudin 18A2 chimeric antigen receptor, T cell modified by same, and preparation method and application of T cell
CN112888458A (en) * 2018-09-30 2021-06-01 佧珐药业有限公司 Combination therapy of antibodies to CLDN18 and chemotherapeutic agents
US20230158071A1 (en) 2018-12-07 2023-05-25 Crage Medical Co., Limited Tumor combined immunotherapy
AU2019391204A1 (en) * 2018-12-07 2021-06-24 Zlip Holding Limited Anti-Claudin antibodies and uses thereof
EP3902839A4 (en) * 2018-12-28 2022-12-14 Nanjing GenScript Biotech Co., Ltd. Claudin18.2 binding moieties and uses thereof
CN113166246A (en) * 2018-12-28 2021-07-23 四川科伦博泰生物医药股份有限公司 Antibody and application thereof
WO2020143631A1 (en) 2019-01-07 2020-07-16 科济生物医药（上海）有限公司 Cellular immunotherapy combination
CN111434692B (en) * 2019-01-15 2021-12-31 浙江道尔生物科技有限公司 anti-CLD18A2 nano antibody and application thereof
CN109762067B (en) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 Antibodies that bind human Claudin18.2 and uses thereof
WO2020156554A1 (en) 2019-02-01 2020-08-06 科济生物医药（上海）有限公司 Tcr fusion protein and cell expressing tcr fusion protein
CA3128502A1 (en) * 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
WO2020198413A1 (en) * 2019-03-27 2020-10-01 The Trustees Of The University Of Pennsylvania Tn-muc1 chimeric antigen receptor (car) t cell therapy
SG11202109052YA (en) * 2019-03-29 2021-10-28 Phanes Therapeutics Inc Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
CN113544156B (en) * 2019-04-01 2022-11-22 江苏恒瑞医药股份有限公司 anti-Claudin18.2 antibody and application thereof
CN113748133B (en) * 2019-04-19 2024-07-02 康诺亚生物医药科技（成都）有限公司 Tumor therapeutic agent and application thereof
CN111978402B (en) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 Novel CLDN18.2 binding molecules
CN114206935B (en) * 2019-05-24 2024-01-12 三优生物医药(上海)有限公司 Novel CLDN18.2 binding molecules
KR20220006085A (en) * 2019-05-30 2022-01-14 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 Antibodies or Chimeric Antigen Receptors Targeting Claudin 18.2
US20220372133A1 (en) * 2019-07-17 2022-11-24 The Regents Of The University Of California Claudin18 antibodies and methods of treating cancer
CN112574307B (en) 2019-09-29 2023-11-28 迈威(上海)生物科技股份有限公司 Anti-human Claudin18.2 antibody and application thereof
EP4054648A4 (en) * 2019-11-05 2023-12-27 LaNova Medicines Limited Antibody-drug conjugates targeting claudin 18.2
US20230000918A1 (en) * 2019-11-29 2023-01-05 Suzhou Nova Therapeutics Co. Ltd Chimeric antigen receptors, compositions and applications thereof
US20230030674A1 (en) 2019-12-06 2023-02-02 Sotio Biotech A.S. Humanized cldn18.2 antibodies
IL294185A (en) 2019-12-23 2022-08-01 Sotio As Tumor-specific claudin 18.2 antibodies
US20230061005A1 (en) * 2020-01-03 2023-03-02 Crage Medical Co., Limited Anti-claudin 18.2 antibody and use thereof
CN115461373B (en) * 2020-02-10 2024-03-29 上海诗健生物科技有限公司 Antibodies to claudin18.2 and uses thereof
WO2021173307A1 (en) * 2020-02-25 2021-09-02 Gensun Biopharma Inc. Trispecific t cell engagers
JP7407973B2 (en) * 2020-05-15 2024-01-04 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド Antibody-drug conjugates, methods of their preparation, and uses thereof
CN111704669B (en) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 anti-CLDN 18 fully humanized antibody for treating advanced gastric cancer
CN113929780A (en) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 Humanized antibody for treating cancer by combining claudin
CN111961135B (en) * 2020-07-13 2022-08-16 北京亦庄国际蛋白药物技术有限公司 Antibody for preventing or treating cancer
CN114222761B (en) * 2020-07-14 2024-02-20 浙江道尔生物科技有限公司 Single domain antibody for resisting CLD18A2
EP4194055A1 (en) 2020-08-07 2023-06-14 CRAGE medical Co., Limited Engineered cells and method for engineering cells
WO2022068854A1 (en) * 2020-09-30 2022-04-07 Nanjing GenScript Biotech Co., Ltd. Antibodies targeting human claudin 18.2 and uses thereof
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
IL303270A (en) 2020-12-21 2023-07-01 Allogene Therapeutics Inc Protease-activating cd45-gate car
US20240100180A1 (en) 2020-12-23 2024-03-28 Sotio Biotech A.S. Tumor-specific claudin 18.2 antibody-drug conjugates
US20220251505A1 (en) 2021-01-29 2022-08-11 Allogene Therapeutics, Inc. KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
EP4321533A1 (en) 2021-04-08 2024-02-14 Crage Medical Co., Limited Cellular immunotherapy use
CN117480247A (en) * 2021-04-15 2024-01-30 恺兴生命科技(上海)有限公司 Chimeric T cell receptor and uses thereof
CN117460741A (en) 2021-06-29 2024-01-26 科济生物医药（上海）有限公司 Chimeric polypeptides for modulating physiological activities of cells
CN115057930B (en) * 2021-09-03 2022-11-29 深圳市先康达生命科学有限公司 Monoclonal antibody targeting human Claudin18.2 protein and application thereof
CN118139888A (en) * 2021-11-05 2024-06-04 正大天晴药业集团股份有限公司 Anti-CLDN 18.2 antibodies and uses thereof
WO2023213280A1 (en) * 2022-05-06 2023-11-09 上海先博生物科技有限公司 Chimeric antigen t cell receptor targeting cldn18.2 and use thereof
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
CN117430708B (en) * 2023-12-21 2024-04-09 苏州近岸蛋白质科技股份有限公司 anti-Claudin18.2 antibody

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
CN112979828A (en) * 2014-07-17 2021-06-18 恺兴生命科技(上海)有限公司 T lymphocyte targeting CLD18A2 and preparation method and application thereof
CN105331585A (en) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 Chimeric antigen receptor-modified immunologic effector cell with PD-L1 blocking agent
PE20181302A1 (en) 2015-12-04 2018-08-09 Abbvie Stemcentrx Llc NEW ANTI-CLAUDIN ANTIBODIES AND THEIR METHODS OF USE
CN118146379A (en) * 2016-04-26 2024-06-07 科济生物医药（上海）有限公司 Method for improving immune response cell function
EP3483182B1 (en) * 2016-07-08 2024-05-08 CRAGE medical Co., Limited Antibody for anti-claudin 18a2 and use thereof
US20220110973A1 (en) * 2018-03-09 2022-04-14 Cafa Therapeutics Limited Method and composition for treating tumors
CN112888458A (en) * 2018-09-30 2021-06-01 佧珐药业有限公司 Combination therapy of antibodies to CLDN18 and chemotherapeutic agents
WO2020143631A1 (en) * 2019-01-07 2020-07-16 科济生物医药（上海）有限公司 Cellular immunotherapy combination
US20230272341A1 (en) * 2020-08-10 2023-08-31 Crage Medical Co., Limited Multifunctional immune effector cell and use thereof

Also Published As

Publication number Publication date
US20190233511A1 (en) 2019-08-01
WO2018006882A1 (en) 2018-01-11
IL264144A (en) 2019-02-28
EP3483182A1 (en) 2019-05-15
CN109790222A (en) 2019-05-21
RU2019101430A3 (en) 2021-05-17
US11111295B2 (en) 2021-09-07
AU2017294276A1 (en) 2019-02-28
KR20190038564A (en) 2019-04-08
CN109790222B (en) 2022-03-15
JP2019531084A (en) 2019-10-31
CL2019000061A1 (en) 2019-05-03
US20220185880A1 (en) 2022-06-16
BR112019000327A2 (en) 2019-08-13
BR112019000327A8 (en) 2022-10-18
RU2019101430A (en) 2020-08-10
CA3030257A1 (en) 2018-01-11
EP3483182A4 (en) 2020-07-29
IL264144B2 (en) 2023-11-01
IL264144B1 (en) 2023-07-01
EP3483182B1 (en) 2024-05-08

Similar Documents

Publication Publication Date Title
SG11201900171QA (en) Antibody for anti-claudin 18a2 and use thereof
PH12019500193A1 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
SG11201906780SA (en) Bcma-targeting antibody and use thereof
MX2019006598A (en) Engineered natural killer cells and uses thereof.
PH12021550152A1 (en) Anti-cd112r compositions and methods
MY194032A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
EP3964527A3 (en) Combination therapy for cancer
SG10201809668TA (en) Anti-her2 antibodies and immunoconjugates
SG10201803042PA (en) Anti-tim-3 antibodies
NZ738008A (en) Tigit-binding agents and uses thereof
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2021013837A (en) Combination immunotherapy approach for treatment of cancer.
MX2019007020A (en) Il-11 antibodies.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
BR112018003339A2 (en) fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
SG10201901707QA (en) Antibodies targeting b-cell maturation antigen and methods of use
MX2019007021A (en) Il-11ra antibodies.
MY191581A (en) Anti-pd-1 antibodies
MX2020011783A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer.
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
MX2021006681A (en) Anti-claudin antibodies and uses thereof.
WO2017139570A8 (en) Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine
MX2018011875A (en) Enhanced direct cardiac reprogramming.